Hikma is introducing mercaptopurine oral suspension, in a 20mg/ml dose, which is the first generic of this product. Hikma was the first approved applicant with a Competitive Generic Therapy ...

Profit margin: 12% (up from 6.6% in FY 2023). The increase in margin was driven by higher revenue. EPS: US$1.62 (up from US$0.86 in FY 2023). Revenue exceeded analyst estimates by 1.3%. Earnings per ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Axsome Therapeutics has entered into a settlement agreement with Hikma resolving patent litigation related to Axsome’s product Sunosi (solriamfetol). The litigation, which is pending in the ...

Nasdaq Dividend History provides straightforward stock’s historical dividends data. Dividend payout record can be used to gauge the company's long-term performance when analyzing individual stocks.

One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). Hikma Pharmaceuticals' earnings per share ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Drugmaker Hikma is in talks with partners across the world to prepare to sell a generic version of Ozempic ...

The litigation, which is pending in the United States District Court for the District of New Jersey, resulted from submission by Hikma of an Abbreviated New Drug Application to the U.S. Food and ...